Supercharged immune cells take on advanced liver cancer

NCT ID NCT07493044

Recruiting now Disease control Sponsor: Guangzhou FineImmune Biotechnology Co., LTD. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new treatment called Super CAR-T for people with advanced hepatocellular carcinoma, a type of liver cancer that has spread. The treatment involves taking a patient's own immune cells, modifying them to better recognize and attack cancer cells, and infusing them back. The main goals are to find a safe dose and check for any serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Super CAR-T cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for advanced liver cancer that is hard to treat.
What could go wrong: This is a very early, small phase 1 trial with only 15 people, so safety and effectiveness are not yet proven. There may be serious side effects from the immune cells or the pre-treatment chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC) GPC3 POSITIVE HEPATOCELLULAR CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Gaungdong, 510700, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.